|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 8
Zeitschriftenartikel
Dempke, Wolfram C. M. und Fenchel, Klaus
(2021):
Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?-a narrative review.
In: Translational Lung Cancer Research, Bd. 10, Nr. 6: S. 2667-2682
Frost, Nikolaj; Christopoulos, Petros; Kauffmann-Guerrero, Diego; Stratmann, Jan; Riedel, Richard; Schaefer, Monica; Alt, Jürgen; Gutz, Sylvia; Christoph, Daniel C.; Laack, Eckart; Faehling, Martin; Fischer, Richard; Fenchel, Klaus; Haen, Sebastian; Heukamp, Lukas; Schulz, Christian und Griesinger, Frank
(2021):
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
In: Therapeutic Advances in Medical Oncology, Bd. 13, 1758835920980558
Manz, Kirsi M. 
ORCID: https://orcid.org/0000-0002-7740-4076; Fenchel, Klaus; Eilers, Andreas; Morgan, Jonathan; Wittling, Kirsten und Dempke, Wolfram C. M. ORCID: https://orcid.org/0000-0002-7683-1017
(14. Dezember 2019):
Efficacy and Safety of Approved First-Line Tyrosine
Kinase Inhibitor Treatments in Metastatic Renal Cell
Carcinoma: A Network Meta-Analysis.
In: Advances in therapy, Bd. 37: S. 730-744
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-7740-4076; Fenchel, Klaus; Eilers, Andreas; Morgan, Jonathan; Wittling, Kirsten und Dempke, Wolfram C. M. ORCID: https://orcid.org/0000-0002-7683-1017
(14. Dezember 2019):
Efficacy and Safety of Approved First-Line Tyrosine
Kinase Inhibitor Treatments in Metastatic Renal Cell
Carcinoma: A Network Meta-Analysis.
In: Advances in therapy, Bd. 37: S. 730-744
[PDF, 1MB]
Dempke, Wolfram C. M.; Fenchel, Klaus; Uciechowski, Peter und Dale, Stephen P.
(2017):
Second- and third-generation drugs for immuno-oncology treatment-The more the better?
In: European Journal of Cancer, Bd. 74: S. 55-72
Dempke, Wolfram C. M.; Fenchel, Klaus; Uciechowski, Peter und Chevassut, Timothy
(2017):
Targeting Developmental Pathways: The Achilles Heel of Cancer?
In: Oncology, Bd. 93, Nr. 4: S. 213-223
Fenchel, Klaus; Dale, Stephen P. und Dempke, Wolfram C. M.
(2016):
Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?
In: Translational Lung Cancer Research, Bd. 5, Nr. 4: S. 373-376
Dempke, Wolfram C. M. und Fenchel, Klaus
(2016):
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
In: Translational Lung Cancer Research, Bd. 5, Nr. 5: S. 538-542
Fenchel, Klaus; Sellmann, Ludger und Dempke, Wolfram C. M.
(2016):
Overall survival in non-small cell lung cancer-what is clinically meaningful?
In: Translational Lung Cancer Research, Bd. 5, Nr. 1: S. 115-119